Tilmovet 300 mg/ml Solution for Injection for cattle and sheep

Authorised

- Tilmicosin

Product identification

Medicine name:
Tilmovet 300 mg/ml Solution for Injection for cattle and sheep

Active substance:
Tilmicosin

Target species:
Cattle
Sheep

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Tilmicosin
300.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cattle**
  - Meat and offal. 70 day
  - Milk. 36 day
- **Sheep**
  - Meat and offal. 42 day
  - Milk. 18 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01FA91

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

France

Available in:

France

Package description:

100 ml Type II amber glass vial sealed with Type I bromobutyl stopper and aluminium cap, supplied in cardboard box. One vial per box.
50 ml Type II amber glass vial sealed with Type I bromobutyl stopper and aluminium cap, supplied in cardboard box. One vial per box.
25 ml Type I amber glass vial sealed with Type I bromobutyl stopper and aluminium cap, supplied in cardboard box. One vial per box.
250 ml Type II amber glass vial sealed with Type I bromobutyl stopper and aluminium cap, supplied in cardboard box. One vial per box.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
HuVepharma

Marketing authorisation date:
4/04/2019

Manufacturing sites for batch release:
Biovet AD

Responsible authority:
French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:
FR/V/8223902 4/2019

Date of authorisation status change:
10/02/2023

Reference member state:
Ireland

Procedure number:
IE/V/0405/001

Concerned member states:
Belgium Bulgaria France Germany Italy Netherlands Poland Portugal Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/05/2025
Download

Combined File of all Documents

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.